- Home
- Publications
- Publication Search
- Publication Details
Title
Evolution of efficacious pangenotypic hepatitis C virus therapies
Authors
Keywords
-
Journal
MEDICINAL RESEARCH REVIEWS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-12-03
DOI
10.1002/med.21554
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure
- (2018) Fred Poordad et al. HEPATOLOGY
- Epistatic Interactions in NS5A of Hepatitis C Virus Suggest Drug Resistance Mechanisms
- (2018) Elena Knops et al. Genes
- Hepatitis C Vaccines, Antibodies, and T Cells
- (2018) Naglaa H. Shoukry Frontiers in Immunology
- Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir
- (2017) Takashi E. Komatsu et al. GASTROENTEROLOGY
- Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure
- (2017) David Wyles et al. HEPATOLOGY
- ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis
- (2017) G.R. Foster et al. JOURNAL OF HEPATOLOGY
- MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure
- (2017) F. Poordad et al. JOURNAL OF HEPATOLOGY
- High sustained virologic response rates in patients with chronic hepatitis C virus GT1, 2 or 3 infection following 16 weeks of MK-3682/grazoprevir/ruzasvir plus ribavirin after having failed 8 weeks of a triplet drug regimen (Part C of C-CREST-1 & 2)
- (2017) L. Serfaty et al. JOURNAL OF HEPATOLOGY
- NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome
- (2017) Stefan Zeuzem et al. JOURNAL OF HEPATOLOGY
- Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis
- (2017) Paul Y. Kwo et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study
- (2017) J. Rockstroh et al. JOURNAL OF HEPATOLOGY
- MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection
- (2017) N. Reau et al. JOURNAL OF HEPATOLOGY
- Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses
- (2017) Tania M. Welzel et al. JOURNAL OF HEPATOLOGY
- Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial
- (2017) Meike H van der Ree et al. LANCET
- The discovery of a pan-genotypic, primer grip inhibitor of HCV NS5B polymerase
- (2017) Kyle J. Eastman et al. MedChemComm
- Identification of Entry Factors Involved in Hepatitis C Virus Infection Based on Host-Mimicking Short Linear Motifs
- (2017) Austin W. T. Chiang et al. PLoS Computational Biology
- Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172
- (2016) Djadé I. Soumana et al. ACS Chemical Biology
- Elbasvir/Grazoprevir: First Global Approval
- (2016) Gillian M. Keating DRUGS
- Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir
- (2016) Christoph Sarrazin et al. GASTROENTEROLOGY
- Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
- (2016) Jean-Michel Pawlotsky GASTROENTEROLOGY
- Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial
- (2016) Eric Lawitz et al. HEPATOLOGY
- Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection
- (2016) Jun Ito et al. HEPATOLOGY RESEARCH
- Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks
- (2016) Jordan J. Feld et al. JOURNAL OF HEPATOLOGY
- The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
- (2016) Christoph Sarrazin JOURNAL OF HEPATOLOGY
- GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study
- (2016) M. Rodriguez-Torres et al. JOURNAL OF VIRAL HEPATITIS
- Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents
- (2016) A. A. Eltahla et al. JOURNAL OF VIRAL HEPATITIS
- Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives
- (2016) Tarik Asselah et al. LIVER INTERNATIONAL
- Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation
- (2016) Ian A. Rowe et al. LIVER TRANSPLANTATION
- Virologic responses and tolerance of peginterferon alfa plus ribavirin treatment for patients with chronic hepatitis C virus infection in different age categories
- (2016) X Chen et al. Nigerian Journal of Clinical Practice
- Infectious Complications With the Use of Biologic Response Modifiers in Infants and Children
- (2016) H. Dele Davies et al. PEDIATRICS
- Hepatitis C Virus Frameshift/Alternate Reading Frame Protein Suppresses Interferon Responses Mediated by Pattern Recognition Receptor Retinoic-Acid-Inducible Gene-I
- (2016) Seung Bum Park et al. PLoS One
- Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China
- (2016) Kali Zhou et al. PLoS One
- Interactome of the hepatitis C virus: Literature mining with ANDSystem
- (2016) Olga V. Saik et al. VIRUS RESEARCH
- Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes
- (2016) Arnolfo Petruzziello et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking
- (2016) Yu Wei et al. PLoS One
- A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
- (2016) Robert Flisiak et al. PLoS One
- Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy
- (2015) Jean Ndjomou et al. ACS Chemical Biology
- Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
- (2015) Stefan Zeuzem et al. ANNALS OF INTERNAL MEDICINE
- Preclinical Characterization andIn VivoEfficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein
- (2015) Jeffrey J. Pouliot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Identification of a lead like inhibitor of the hepatitis C virus non-structural NS2 autoprotease
- (2015) Joseph Shaw et al. ANTIVIRAL RESEARCH
- Epoxide based inhibitors of the hepatitis C virus non-structural 2 autoprotease
- (2015) Joseph Shaw et al. ANTIVIRAL RESEARCH
- The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro
- (2015) Véronique Descamps et al. ANTIVIRAL RESEARCH
- Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6
- (2015) Maxim V. Kozlov et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials
- (2015) Saleh A. Alqahtani et al. HEPATOLOGY
- Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
- (2015) Eric Lawitz et al. HEPATOLOGY
- Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
- (2015) Fred Poordad et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2
- (2015) E. Lawitz et al. JOURNAL OF HEPATOLOGY
- LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1
- (2015) P. Kwo et al. JOURNAL OF HEPATOLOGY
- O057 : Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens
- (2015) P. Krishnan et al. JOURNAL OF HEPATOLOGY
- Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
- (2015) Christophe Hézode et al. LANCET
- Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
- (2015) Marc Bourlière et al. LANCET INFECTIOUS DISEASES
- A Combined Proteomics/Genomics Approach Links Hepatitis C Virus Infection with Nonsense-Mediated mRNA Decay
- (2015) Holly R. Ramage et al. MOLECULAR CELL
- Boronic acid-modified lipid nanocapsules: a novel platform for the highly efficient inhibition of hepatitis C viral entry
- (2015) Manakamana Khanal et al. Nanoscale
- Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody
- (2015) Laurent Mailly et al. NATURE BIOTECHNOLOGY
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
- (2015) Graham R. Foster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
- (2015) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
- (2015) Susanna Naggie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications
- (2015) Celia Perales et al. Viruses-Basel
- Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor
- (2015) Santhosh F. Neelamkavil et al. ACS Medicinal Chemistry Letters
- Host APOBEC3G Protein Inhibits HCV Replication through Direct Binding at NS3
- (2015) Yan-Ping Zhu et al. PLoS One
- Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent
- (2015) Hyock Joo Kwon et al. PLoS One
- The Combination of Alisporivir plus an NS5A Inhibitor Provides Additive to Synergistic Anti-Hepatitis C Virus Activity without Detectable Cross-Resistance
- (2014) Udayan Chatterji et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection
- (2014) Karen D. Sims et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroandIn VivoAntiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A
- (2014) Preethi Krishnan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Current race in the development of DAAs (direct-acting antivirals) against HCV
- (2014) Erik De Clercq BIOCHEMICAL PHARMACOLOGY
- RACK1 Controls IRES-Mediated Translation of Viruses
- (2014) Karim Majzoub et al. CELL
- Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
- (2014) Evguenia S. Svarovskaia et al. CLINICAL INFECTIOUS DISEASES
- Editorial Commentary: Barrier to Resistance: Lessons From 2 Direct-Acting Hepatitis C Virus Inhibitors, MK-5172 and Sofosbuvir
- (2014) X. Tong et al. CLINICAL INFECTIOUS DISEASES
- Daclatasvir-Like Inhibitors of NS5A Block Early Biogenesis of Hepatitis C Virus–Induced Membranous Replication Factories, Independent of RNA Replication
- (2014) Carola Berger et al. GASTROENTEROLOGY
- ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
- (2014) Pietro Andreone et al. GASTROENTEROLOGY
- Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors
- (2014) David R. McGivern et al. GASTROENTEROLOGY
- Inhibition of HCV Replication by Cyclophilin Antagonists Is Linked to Replication Fitness and Occurs by Inhibition of Membranous Web Formation
- (2014) Vanesa Madan et al. GASTROENTEROLOGY
- Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
- (2014) Christophe Hézode et al. GUT
- Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
- (2014) Fei Xiao et al. GUT
- Antibodies to the high-density lipoprotein receptor SR-B1 potently inhibit hepatitis C virus replicationin vivo: New avenues for preventing reinfection of the liver following transplantation
- (2014) Heidi E. Drummer HEPATOLOGY
- Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir
- (2014) Eric F. Donaldson et al. HEPATOLOGY
- Multiple e-Pharmacophore Modeling, 3D-QSAR, and High-Throughput Virtual Screening of Hepatitis C Virus NS5B Polymerase Inhibitors
- (2014) Patrisha Joseph Therese et al. Journal of Chemical Information and Modeling
- A Refined Model of the HCV NS5A Protein Bound to Daclatasvir Explains Drug-Resistant Mutations and Activity against Divergent Genotypes
- (2014) Khaled H. Barakat et al. Journal of Chemical Information and Modeling
- A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection
- (2014) Andrew J. Muir et al. JOURNAL OF HEPATOLOGY
- Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
- (2014) Paul M. Scola et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
- (2014) Paul M. Scola et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel Spiroketal Pyrrolidine GSK2336805 Potently Inhibits Key Hepatitis C Virus Genotype 1b Mutants: From Lead to Clinical Compound
- (2014) Wieslaw M. Kazmierski et al. JOURNAL OF MEDICINAL CHEMISTRY
- Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir
- (2014) Makonen Belema et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect
- (2014) Makonen Belema et al. JOURNAL OF MEDICINAL CHEMISTRY
- Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition
- (2014) James H. Nettles et al. JOURNAL OF MEDICINAL CHEMISTRY
- Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Michael Manns et al. LANCET
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
- (2014) Eric Lawitz et al. LANCET
- Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study
- (2014) Stefan Zeuzem et al. LIVER INTERNATIONAL
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
- (2014) Peter Ferenci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1–P2 ligands
- (2014) Arun K. Ghosh et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Computational Study on the Inhibitor Binding Mode and Allosteric Regulation Mechanism in Hepatitis C Virus NS3/4A Protein
- (2014) Weiwei Xue et al. PLoS One
- Dendritic Cell-Mediated, DNA-Based Vaccination against Hepatitis C Induces the Multi-Epitope-Specific Response of Humanized, HLA Transgenic Mice
- (2014) Sasmita Mishra et al. PLoS One
- The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors
- (2014) Sebastian M. Lambert et al. PROTEIN SCIENCE
- A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
- (2014) L. Swadling et al. Science Translational Medicine
- Novel Quinoline-Based P2–P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors
- (2014) Unmesh Shah et al. ACS Medicinal Chemistry Letters
- Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV/HCV co-infected patients in a Berlin laboratory
- (2014) Robert Ehret et al. Journal of the International AIDS Society
- Identification of PTC725, an Orally Bioavailable Small Molecule That Selectively Targets the Hepatitis C Virus NS4B Protein
- (2013) Zhengxian Gu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885
- (2013) Kelly A. Wong et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Phosphatidylinositol 4-Kinase III Beta Is Essential for Replication of Human Rhinovirus and Its Inhibition Causes a Lethal PhenotypeIn Vivo
- (2013) Catherine Spickler et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
- (2013) Gregory T. Everson et al. GASTROENTEROLOGY
- Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial
- (2013) Stefan Zeuzem et al. GASTROENTEROLOGY
- Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource
- (2013) Donald B. Smith et al. HEPATOLOGY
- Hepatitis C virus induced up-regulation of microRNA-27: A novel mechanism for hepatic steatosis
- (2013) Ragunath Singaravelu et al. HEPATOLOGY
- 1209 TREATMENT-EMERGENT VARIANTS FOLLOWING 3 DAYS OF MONOTHERAPY WITH IDX719, A POTENT, PAN-GENOTYPIC NS5A INHIBITOR, IN SUBJECTS INFECTED WITH HCV GENOTYPES 1–4
- (2013) J.F. McCarville et al. JOURNAL OF HEPATOLOGY
- Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study
- (2013) Mark S. Sulkowski et al. JOURNAL OF INFECTIOUS DISEASES
- Understanding the Biological Context of NS5A–Host Interactions in HCV Infection: A Network-Based Approach
- (2013) Lokesh P. Tripathi et al. JOURNAL OF PROTEOME RESEARCH
- Cellular immunogenicity of a multi-epitope peptide vaccine candidate based on hepatitis C virus NS5A, NS4B and core proteins in HHD-2 mice
- (2013) Xiao-jun Huang et al. JOURNAL OF VIROLOGICAL METHODS
- Hepatocyte Nuclear Factor 4 and Downstream Secreted Phospholipase A2 GXIIB Regulate Production of Infectious Hepatitis C Virus
- (2013) X. Li et al. JOURNAL OF VIROLOGY
- Nitazoxanide plus pegylated interferon and ribavirin in the treatment of genotype 4 chronic hepatitis C, a randomized controlled trial
- (2013) Hany M. Shehab et al. LIVER INTERNATIONAL
- New therapeutic strategies in HCV: polymerase inhibitors
- (2013) Ludmila Gerber et al. LIVER INTERNATIONAL
- Elucidating Novel Hepatitis C Virus–Host Interactions Using Combined Mass Spectrometry and Functional Genomics Approaches
- (2013) Marie-Anne Germain et al. MOLECULAR & CELLULAR PROTEOMICS
- Identification and comparative analysis of hepatitis C virus–host cell protein interactions
- (2013) Patrick T. Dolan et al. Molecular BioSystems
- Inhibition of Hepatitis C Virus by the Cyanobacterial Protein Microcystis viridis Lectin: Mechanistic Differences between the High-Mannose Specific Lectins MVL, CV-N, and GNA
- (2013) Alla Kachko et al. MOLECULAR PHARMACEUTICS
- Completion of the entire hepatitis C virus life cycle in genetically humanized mice
- (2013) Marcus Dorner et al. NATURE
- Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly
- (2013) Qisheng Li et al. NATURE MEDICINE
- The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
- (2013) Ralf Bartenschlager et al. NATURE REVIEWS MICROBIOLOGY
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
- (2013) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
- (2013) Edward J. Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV Infection by Targeting MicroRNA
- (2013) Harry L.A. Janssen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
- (2013) J. Guedj et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The interdomain interface in bifunctional enzyme protein 3/4A (NS3/4A) regulates protease and helicase activities
- (2013) Cihan Aydin et al. PROTEIN SCIENCE
- Characterizations of HCV NS5A replication complex inhibitors
- (2013) Donald R. O'Boyle II et al. VIROLOGY
- The Lipid Kinase Phosphatidylinositol-4 Kinase III Alpha Regulates the Phosphorylation Status of Hepatitis C Virus NS5A
- (2013) Simon Reiss et al. PLoS Pathogens
- Hepatitis C Virus p7 is Critical for Capsid Assembly and Envelopment
- (2013) Juliane Gentzsch et al. PLoS Pathogens
- Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells
- (2012) Mohsan Saeed et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Induction of humoral and cellular immune responses against hepatitis C virus by vaccination with replicon particles derived from Sindbis-like virus XJ-160
- (2012) Wuyang Zhu et al. ARCHIVES OF VIROLOGY
- A highly selective structure-based virtual screening model of Palm I allosteric inhibitors of HCV Ns5b polymerase enzyme and its application in the discovery and optimization of new analogues
- (2012) Amr H. Mahmoud et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities
- (2012) Farzin Roohvand et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice
- (2012) Krzysztof Lacek et al. JOURNAL OF HEPATOLOGY
- A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
- (2012) Eric J. Lawitz et al. JOURNAL OF HEPATOLOGY
- Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period
- (2012) Rafael Bárcena et al. JOURNAL OF HEPATOLOGY
- Structure of Hepatitis C Virus Polymerase in Complex with Primer-Template RNA
- (2012) R. T. Mosley et al. JOURNAL OF VIROLOGY
- Hepatitis C Virus Induces Epidermal Growth Factor Receptor Activation via CD81 Binding for Viral Internalization and Entry
- (2012) J. Diao et al. JOURNAL OF VIROLOGY
- Identification of the Niemann-Pick C1–like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor
- (2012) Bruno Sainz et al. NATURE MEDICINE
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
- (2012) Anna S. Lok et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL28B Genetic Variation Is Associated with Spontaneous Clearance of Hepatitis C Virus, Treatment Response, Serum IL-28B Levels in Chinese Population
- (2012) Xiaodong Shi et al. PLoS One
- Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man
- (2012) E. Barnes et al. Science Translational Medicine
- Cyclophilin Inhibitors: An Emerging Class of Therapeutics for the Treatment of Chronic Hepatitis C Infection
- (2012) Sam Hopkins et al. Viruses-Basel
- Neutralizing Antibodies and Pathogenesis of Hepatitis C Virus Infection
- (2012) Samira Fafi-Kremer et al. Viruses-Basel
- Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees
- (2012) Trevor J. Morin et al. PLoS Pathogens
- Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV
- (2011) J. F. Bergmann et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Griffithsin Has Antiviral Activity against Hepatitis C Virus
- (2011) Philip Meuleman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy
- (2011) Eric Lawitz et al. ANTIVIRAL RESEARCH
- Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435
- (2011) Weiwei Xue et al. ANTIVIRAL RESEARCH
- Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7
- (2011) Andre Boonstra et al. ANTIVIRAL THERAPY
- A Poxvirus Vaccine Is Safe, Induces T-Cell Responses, and Decreases Viral Load in Patients With Chronic Hepatitis C
- (2011) François Habersetzer et al. GASTROENTEROLOGY
- Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection
- (2011) Stefan Zeuzem et al. GASTROENTEROLOGY
- Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
- (2011) Kazuaki Chayama et al. HEPATOLOGY
- Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir
- (2011) Simone Susser et al. JOURNAL OF CLINICAL VIROLOGY
- Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism
- (2011) Jonathan Goldwasser et al. JOURNAL OF HEPATOLOGY
- Clearance of Genotype 1b Hepatitis C Virus in Chimpanzees in the Presence of Vaccine-Induced E1-Neutralizing Antibodies
- (2011) Babs E. Verstrepen et al. JOURNAL OF INFECTIOUS DISEASES
- Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase
- (2011) Michael J. Sofia et al. JOURNAL OF MEDICINAL CHEMISTRY
- An Objective Assessment of Conformational Variability in Complexes of Hepatitis C Virus Polymerase with Non-Nucleoside Inhibitors
- (2011) Célia Caillet-Saguy et al. JOURNAL OF MOLECULAR BIOLOGY
- Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052
- (2011) R. A. Fridell et al. JOURNAL OF VIROLOGY
- Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
- (2011) Ann D Kwong et al. NATURE BIOTECHNOLOGY
- EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy
- (2011) Joachim Lupberger et al. NATURE MEDICINE
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Retreatment of HCV Infection
- (2011) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly
- (2011) Costin-Ioan Popescu et al. PLoS Pathogens
- A small molecule inhibits HCV replication and alters NS4B's subcellular distribution
- (2010) Paul D. Bryson et al. ANTIVIRAL RESEARCH
- Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase
- (2010) Tanaji T. Talele et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection
- (2010) Andrew J. Muir et al. HEPATOLOGY
- Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers
- (2010) Debbie Drane et al. Human vaccines & immunotherapeutics
- Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977
- (2010) Eisuke Murakami et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Combining 3-D Quantitative Structure−Activity Relationship with Ligand Based and Structure Based Alignment Procedures forin SilicoScreening of New Hepatitis C Virus NS5B Polymerase Inhibitors
- (2010) Ira Musmuca et al. Journal of Chemical Information and Modeling
- HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A–cyclophilin A interaction to cyclophilin inhibitors
- (2010) Udayan Chatterji et al. JOURNAL OF HEPATOLOGY
- Hepatitis C virus replication cycle
- (2010) Ralf Bartenschlager et al. JOURNAL OF HEPATOLOGY
- The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole Is Highly Synergistic with HCV Protease Inhibitors
- (2010) Shirit Einav et al. JOURNAL OF INFECTIOUS DISEASES
- Discovery of a Potent and Selective Noncovalent Linear Inhibitor of the Hepatitis C Virus NS3 Protease (BI 201335)
- (2010) Montse Llinàs-Brunet et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
- (2010) John A. McCauley et al. JOURNAL OF MEDICINAL CHEMISTRY
- Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
- (2010) Edward J Gane et al. LANCET
- Network based analysis of hepatitis C virus Core and NS4B protein interactions
- (2010) Lokesh P. Tripathi et al. Molecular BioSystems
- Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1
- (2010) Eva Herker et al. NATURE MEDICINE
- A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle
- (2010) Karuppiah Chockalingam et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding
- (2010) K. P. Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of a Class of HCV Inhibitors Directed Against the Nonstructural Protein NS4B
- (2010) N.-J. Cho et al. Science Translational Medicine
- Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B
- (2010) Megan H. Powdrill et al. Viruses-Basel
- Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor
- (2010) Ashok Arasappan et al. ACS Medicinal Chemistry Letters
- Hepatitis C virus experimental model systems and antiviral drug research
- (2010) Susan L. Uprichard VIROLOGICA SINICA
- SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro
- (2009) S. Hopkins et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Mathematical Model of Hepatitis C Virus Dynamics in Patients With High Baseline Viral Loads or Advanced Liver Disease
- (2009) Harel Dahari et al. GASTROENTEROLOGY
- Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-Claudin-1 associations
- (2009) Sophie E. Krieger et al. HEPATOLOGY
- Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A
- (2009) Sandra Ciesek et al. HEPATOLOGY
- Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy
- (2009) Tomokazu Mizui et al. JOURNAL OF GASTROENTEROLOGY
- Structure-Based Discovery of Triphenylmethane Derivatives as Inhibitors of Hepatitis C Virus Helicase∞
- (2009) Chien-Shu Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Class III Phosphatidylinositol 4-Kinase Alpha and Beta Are Novel Host Factor Regulators of Hepatitis C Virus Replication
- (2009) J. Borawski et al. JOURNAL OF VIROLOGY
- Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants
- (2009) M. T. Catanese et al. JOURNAL OF VIROLOGY
- Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus
- (2009) R. A. Love et al. JOURNAL OF VIROLOGY
- Human occludin is a hepatitis C virus entry factor required for infection of mouse cells
- (2009) Alexander Ploss et al. NATURE
- IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
- (2009) Vijayaprakash Suppiah et al. NATURE GENETICS
- Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection
- (2009) P. Gastaminza et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection
- (2009) R. E. Lanford et al. SCIENCE
- Targeting host factors: A novel rationale for the management of hepatitis C virus
- (2009) Mahmoud Aboelneen Khattab WORLD JOURNAL OF GASTROENTEROLOGY
- Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors
- (2008) L. Coelmont et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors
- (2008) J. Paeshuyse et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Therapeutic Vaccination of Chronic Hepatitis C Nonresponder Patients With the Peptide Vaccine IC41
- (2008) Christoph S. Klade et al. GASTROENTEROLOGY
- The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus
- (2008) Robert Flisiak et al. HEPATOLOGY
- Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo
- (2008) Philip Meuleman et al. HEPATOLOGY
- 66 POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR R7128 WITH PEG-IFN AND RIBAVIRIN: INTERIM RESULTS OF R7128 500MG BID FOR 28 DAYS
- (2008) J. Lalezari et al. JOURNAL OF HEPATOLOGY
- Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis
- (2008) Shirit Einav et al. NATURE BIOTECHNOLOGY
- Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting
- (2007) Fujun Li et al. JOURNAL OF PHARMACEUTICAL SCIENCES
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now